Breaking Ground in GU Cancers

Andrew Smith
Published: Monday, Feb 17, 2020
Daniel P. Petrylak, MD

Daniel P. Petrylak, MD
Less than a decade ago, it was difficult to get pharmaceutical companies interested in conducting trials in bladder cancer. Thanks to breakthrough treatments pioneered by investigators such as Daniel P. Petrylak, MD, that has changed. Anti–PD-1/PD-L1 agents helped open the door to better outcomes, and most recently the FDA granted accelerated approval to enfortumab vedotin-ejfv (Padcev), an antibody-drug conjugate that demonstrated an overall response rate (ORR) of 44% in patients with locally advanced or metastatic urothelial cancer in the EV-201 trial (NCT03219333).1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication